Home > Insider Trading > Filing (0001209191-19-062325)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1645460	Cue Biopharma Inc.	CUE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
897744	A Christopher Marlett	2425 Cedar Springs Road Dallas TX 75201		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-12-27	9,000	$17.24	775,203	No	4	S	Indirect	See footnote
Common Stock	Disposition	2019-12-31	6,700	$15.77	768,503	No	4	S	Indirect	See footnote
Common Stock	Disposition	2019-12-31	9,000	$15.71	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.01 to $17.56, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $16.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $15.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.